BRIEF—Positive UK reimbursement decision for Celgene

Celgene has won a positive UK reimbursement decision for Revlimid (lenalidomide) in combination with dexamethasone for multiple myeloma in certain adults, in the first-line setting.

The recommendation means that people across the UK can now access lenalidomide earlier in the treatment pathway.

A positive decision was also granted for lenalidomide plus dexamethasone as an option for treating multiple myeloma in adults in the second-line setting.